Due Diligence

This service is designed for investors, VCs and licensees who require an independent view on the quality of the pre-clinical data package for a small molecule asset prior to investing or licensing.

It is also designed for licensors to evaluate their data package prior to licensing and for organisations reviewing their internal portfolio to determine how resources should be allocated.